Significant Advances in ALS Research with ATH-1105
Athira Pharma, Inc. (NASDAQ: ATHA), a pioneering biopharmaceutical company, is making strides in the fight against amyotrophic lateral sclerosis (ALS). Recent preclinical data presented at an esteemed symposium on motor neuron diseases highlight the potential of ATH-1105, a small-molecule positive modulator that targets the neurotrophic HGF system. This innovative work positions ATH-1105 as a promising candidate in ALS research focused on restoring neuronal health.
Unveiling Neuroprotective Effects
During the recent presentation, key findings were revealed showing ATH-1105's neuroprotective effects specifically in human motor neuron models. Kevin Church, Ph.D., Chief Scientific Officer of Athira, emphasized that this marks the first successful demonstration of ATH-1105's effects on human models of ALS. Researchers explored its interaction with human induced pluripotent stem cell-derived (iPSC) motor neurons, particularly those impacted by the SOD1-A4V mutation, a common genetic cause of ALS.
Overview of Presentation
Dr. Sherif Reda, Associate Director of Discovery Biology at Athira, presented the data at a prominent medical symposium. The presentation was titled, "ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective in co-culture of human iPSC-derived motor neurons and muscle.” It showcased how ATH-1105 could revolutionize treatment methods for ALS.
Promising Findings from the Study
The data shared included several crucial highlights:
- ATH-1105 triggered MET receptor activation in motor neurons derived from ALS patients.
- Notably, the compound significantly increased motor neuron survival and protected neurite networks against glutamate-induced challenges, demonstrating its protective mechanism in primary spinal motor neurons.
- Further examination revealed that ATH-1105's neuroprotective benefits hinged on the MET receptor; its effects vanished when MET was knocked down using siRNA techniques.
- In a sophisticated neuromuscular junction model using human iPSC-derived SOD1A4V motor neurons and muscle cells, ATH-1105 was found to enhance survival rates and safeguard neurite networks from glutamate toxicity.
ATH-1105: A Hopeful Future for ALS Treatment
ATH-1105 is currently advancing through a Phase 1 trial, designed to assess both safety and tolerability while evaluating the pharmacokinetics of this innovative compound. As an oral therapy capable of penetrating the brain, ATH-1105 holds promise not only for ALS but also for other neurodegenerative conditions.
Details on the Clinical Trial
The ongoing double-blind, placebo-controlled trial involves volunteers aiming to better understand the effects and potential of ATH-1105. This study could pave the way for groundbreaking therapeutic approaches in treating ALS and improving the quality of life for those affected.
About Athira Pharma
Athira Pharma is on a mission to modify the course of neurological disorders through its innovative treatments. With a dedicated focus on the neurotrophic HGF pathway, the company continues to explore and develop a robust pipeline aimed at revitalizing neuronal health. Our goal is clear: to bring transformative therapies to patients grappling with debilitating neurodegenerative diseases.
Contacting Athira
For interested parties seeking more information, Athira encourages reaching out to the following contacts:
Investor & Media Contact: Julie Rathbun, 206-769-9219, Julie.rathbun@athira.com
Corporate Development Contact: Maya Kneip, 206-412-9078, Maya.kneip@athira.com
Frequently Asked Questions
What is ATH-1105?
ATH-1105 is a small-molecule drug candidate developed by Athira Pharma aimed at treating ALS and other neurodegenerative diseases.
What were the key findings presented about ATH-1105?
The presentation highlighted its neuroprotective effects in human motor neurons, showcasing its ability to enhance survival and protect neurite networks.
Who presented the data for ATH-1105?
Dr. Sherif Reda, Associate Director of Discovery Biology at Athira, presented the findings at the International Symposium on ALS/MND.
What does the ongoing clinical trial involve?
The Phase 1 clinical trial is evaluating the safety and tolerability of ATH-1105 through monitoring various pharmacokinetic outcomes.
How can I contact Athira Pharma for more information?
You can reach out via email to investor relations at Julie.rathbun@athira.com or corporate development at Maya.kneip@athira.com.
